1
Test before you eliminate
Carry more credible hits into physical IgG testing instead of choosing the winners while they are still only sequences, display hits or model outputs.
Better antibody decisions, earlier
Find the antibody worth developing.
Before development gets expensive.
Every discovery campaign creates more plausible antibodies than you can afford to carry forward. Fynd Bio makes full-length, glycosylated IgGs in hours, so you can put more candidates through physical testing before deciding which ones deserve the expensive work.
For research use only. Expression performance depends on sequence and workflow conditions.
<24 hourssequence-to-protein workflow
HEK or CHOglycosylated full-length IgGs
Keep more candidates in playLet experimental evidence—not expression time—do more of the narrowing.
Mammalian glycosylationScreen full-length IgGs in HEK- or CHO-derived systems.
Spend later, learn earlierUse screening-scale material to learn first. Scale the antibodies that earn it.
Discovery economics
The most expensive antibody is the wrong one you chose too early.
The first few micrograms can answer questions that determine whether the next milligram is worth making. Fynd moves physical IgG testing earlier—when changing your mind is still cheap—so more of the funnel is narrowed by data rather than production constraints.
2
Use the molecule you care about
Compare candidates as full-length, glycosylated IgGs before committing to a lead on the basis of a surrogate format.
3
Scale after the evidence
Make screening-scale material for the decision in front of you. Move to conventional production when a candidate has earned the next investment.
Molecular fidelity
Screen closer to the IgG you plan to develop.
Fynd Bio produces full-length, glycosylated IgGs in mammalian cell-free systems. Choose a human HEK- or CHO-derived environment so early ranking is based on a more relevant molecular format. Glycosylation can significantly affect developability, binding kinetics and Fc function.
See the primary evidence →Human HEKHuman-derived mammalian glycosylation environment.
CHOCHO-derived mammalian glycosylation environment.
How it works
Put physical IgG evidence earlier in the funnel.
Discovery is increasingly good at generating candidates. The bottleneck is turning enough of them into the physical molecule you actually want to compare. Fynd compresses that step without requiring intact-cell growth or transfection.
1
Start with DNA
Use compatible linear or plasmid templates. For workflows that already generate DNA, ask us about direct template strategies that can reduce unnecessary rebuilding between discovery and expression.
2
Produce full-length IgG
Generate assembled, glycosylated antibody in a human HEK- or CHO-derived cell-free environment without growing or transfecting intact cells.
3
Use it to answer the next question
Take the IgG into the assay that determines what happens next—binding, kinetics, developability, functional screening or your own downstream workflow.
Experimental evidence
Speed only matters if you trust what you made.
Fynd is built around a simple standard: rapid expression should not require you to abandon the molecular features you are trying to evaluate. The platform has produced full-length trastuzumab IgG in mammalian cell-free reactions, with HEK- and CHO-derived systems providing mammalian glycosylation environments and related workflows supporting rapid binding measurements.
Full-length, glycosylated IgG expression
Choose a human HEK or CHO-derived system. Non-reducing and reducing SDS-PAGE workflows provide direct confirmation of assembled IgG and heavy/light chains.
Functional binding readout
Cell-free-produced binders can move rapidly into affinity testing, including measurements from crude reaction material.
Applications
Different discovery engines. The same physical bottleneck.
AI, display, B-cell discovery and lead optimization create candidates in very different ways. They converge on the same question: which sequences are worth carrying forward as full-length IgGs?
AI & computational design
Models can generate candidates faster than conventional expression can validate them. Turn more designs into physical IgG data per round, then feed the evidence back into the next design cycle.
Display & surrogate-format hits
A hit in phage, yeast, Fab, scFv or another discovery context is not yet the therapeutic-format molecule. Re-test more winners as full-length, glycosylated IgGs before the funnel closes.
Read the evidence →B-cell & repertoire discovery
B-cell workflows can recover large numbers of paired antibody sequences—and in some workflows, physical DNA as well. Fynd can help move those hits toward screening-scale IgG without treating every candidate like a development-scale production project.
Lead optimization & variant panels
When one lead becomes dozens or hundreds of CDR, Fc or combination variants, make enough of each to compare the neighborhood before scaling the winners.
Learn more before you spend more.
Tell us what enters your funnel, how many candidates you currently express, and what experiment determines which ones survive. We’ll help you move that experiment earlier with screening-scale, full-length IgG.